Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about a user trying a new hair loss treatment, Ruxolitinib, alongside their existing regimen of finasteride, minoxidil, ketoconazole shampoo, and microneedling. They plan to apply Ruxolitinib to their temples daily for 1-2 months.

Kintor Pharmaceutical's Phase 2 results with the drug Pyrilutamide, a potential alternative to 5-ARI drugs like Finasteride and Dutasteride but without the side effects. It could be used in combination with other topical treatments such as Minoxidil. The safety of the drug has been demonstrated in 6 months of use, however there are still questions about long term efficacy and systemic absorption.

This conversation humorously criticizes DHT for causing hair loss. Treatments mentioned include finasteride and dutasteride.

A potential update on the progress of pyrilutamide, a hair loss treatment; and if Kintor should stop their trials.

User suggests finding unknown baldness cure by applying random items on scalp and reporting results after 6 months. Various users humorously agree to try different substances, including whale sperm and hydrochloric acid.

PP405 is seen as a potential breakthrough for converting vellus hairs to terminal hairs, with users expressing both hope and skepticism. It is compared to treatments like minoxidil and finasteride, with discussions on side effects and marketing concerns.

The conversation is about baricitinib, a medicine that can help with hair loss, and why it isn't more popular or widely discussed. No specific experiences with the treatment were shared.

The user's experience of using Finasteride 5mg and Aldactone 50mg to treat Female Pattern Hair Loss, as well as their use of PRP injections for further hair growth.

The user is using a hair loss regimen involving 2ddr applied twice daily, tretinoin weekly, and occasionally micro-needling. They report feeling increased scalp thickness and seeing some hair growth progress.

The conversation discusses alternatives to 5AR inhibitors for hair loss treatment, suggesting options like minoxidil, KX-826, pyrilutimide, microneedling, and topical bicalutamide. Concerns about side effects and the effectiveness of these treatments are also highlighted.

The conversation discusses GT20029, a drug in Phase II trials that targets androgen receptors with minimal systemic effects, and TDM-105795, a growth stimulant with a different mechanism than minoxidil that may revive papilla stem cells. Both are potential new treatments for hair loss.

The conversation is about a user trying a 0.2% Alfatrafiol treatment for hair loss, combined with Kx826, Minoxidil, microneedling, and ketoconazole. The user reports reduced itching and discusses sourcing the treatment.

RU58841 from rudirect caused more hair shedding and itch, while anageninc's RU58841 improved the situation. Users are concerned about the quality and authenticity of RU58841 from different suppliers, including those from China.

The conversation humorously discusses two resilient hair strands that resist DHT, with mentions of minoxidil and finasteride as ineffective treatments. Users joke about cloning the hairs and the mystery of baldness.

The conversation is about someone experiencing hair regrowth using Minoxidil and Dutasteride, along with other treatments. They report their hairline is improving and their forehead appears smaller.

The user experienced hairline improvement using topical 5% Minoxidil in the first month and 8% Minoxidil with 0.3% topical finasteride in the second month, along with batana oil, Vitamin D, and biotin. The user takes two doses daily and reports a thicker, stronger hairline.

The launch of Pyrilutamide as a potential hair loss treatment, with people discussing whether it is better than treatments like finasteride and minoxidil. Some participants have also discussed the risks associated with importing drugs from China.

A 21-year-old male has been using finasteride 1mg and minoxidil 5% daily for 45 days, noticing some new hair growth but continued hair loss. A reply suggests he is likely shedding and should give it more time for better results.

The conversation discusses the safety study of PP405, emphasizing that early trials focus on safety rather than efficacy, and that any efficacy data from such a short study should be viewed skeptically. It also highlights that the information released is primarily for securing funding, and that meaningful efficacy results are expected in later phases.

Hair loss discussion includes potential HMI-115 treatment. Topical mucuna pruriens shows good results, blocking prolactin possibly more important than blocking DHT.

The conversation discusses hair loss treatments, specifically Breezula, Minoxidil, finasteride, and RU58841. Participants express curiosity about Breezula's safety and its steroidal nature.

Ell-Cranell and Eucapil are discussed as hair loss treatments, with Ell-Cranell being a weak estrogen and DHT inhibitor that may reduce hair loss without systemic side effects. Alfatradiol is the active ingredient in these products.

The conversation discusses hair loss treatments, specifically mentioning Minoxidil, finasteride, and RU58841. It also references upcoming trial data from Shiseido in Japan.

The conversation discusses the lack of promising results from the 23rd Annual Meeting of Japan Society of Clinical Hair Restoration, with no significant advancements expected in the next five years. Treatments mentioned include setipiprant, with skepticism about its effectiveness.

Clascoterone is being discussed as a promising new hair loss treatment, showing significant improvement in trials. Despite this, skepticism persists about its effectiveness, cost, and side effects, with some users preferring minoxidil and finasteride.

The conversation is a satirical discussion about hair loss treatments, with users joking about immediate and exaggerated results from finasteride, dutasteride, and other treatments like microneedling and minoxidil. Some users mock concerns about side effects and the idea of posting rapid progress updates.

The user experimented with finasteride to reduce hair loss and plans to test if creatine affects DHT levels while on finasteride. Initial results showed low DHT levels, indicating finasteride's effectiveness, with further tests planned for creatine's impact.

DUPA is considered more treatable than FAPD, as FAPD involves scarring that prevents hair regrowth. The user has started treatment with oral dutasteride and minoxidil, hoping for better results than previous treatments.

Verteporfin is being discussed for its potential to regrow hair and heal scars, possibly aiding hair transplants or replacing them. Some users are skeptical about its effectiveness, while others suggest combining it with microneedling for better results.

A 25-year-old male experienced noticeable temple regrowth using 1mg finasteride, 2.5mg oral minoxidil, and 2mg GHK-Cu over three months. The user is pleased with the progress, especially on the left temple.